US Merger & Acquisition SEC Filings — July 13, 2026

13-07-2026

Future Vision II Acquisition Corp. (FVNNR) issued a $191,475 unsecured promissory note to HWei Super Speed Co. Ltd. to fund a one-month extension of its deadline to complete a business combination, from July 13, 2026 to August 13, 2026. The note carries no interest and is convertible into units at $10.00 per unit upon a business combination, but is forgiven if no deal closes. This extension loan signals the SPAC is still pursuing a merger but has not yet consummated a business combination, and the note's conversion feature is capped at $1,500,000 aggregate.

• · The note is unsecured, bears no interest, and is payable upon consummation of a business combination.
• · Proceeds must be deposited into the trust account to extend the business combination deadline from July 13, 2026 to August 13, 2026.
• · The note can be converted into units at $10.00 per unit, identical to placement units from the IPO private placement.
• · Conversion is capped at an aggregate $1,500,000 across all similar working capital/extension loans from the Payee and affiliates.
• · If no business combination occurs by the extended deadline, the note is forgiven and the Payee has no right to payment.
• · The Payee waives any claim to the trust account distributions.
• · The note is governed by New York law and cannot be assigned without Maker's consent prior to a business combination.

13-07-2026

Athena Technology Acquisition Corp. II deposited $271.48 into its trust account to extend the deadline to complete an initial business combination by one month, from July 14, 2026 to August 14, 2026. This is the second of up to nine potential monthly extensions available under the company's charter. The filing indicates the SPAC is still searching for a target and has not yet consummated a business combination.

• · The extension period runs from July 14, 2026 to August 14, 2026.
• · The company is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.

13-07-2026

Franklin Street Properties Corp. completed the sale of a property in Englewood, Colorado for $19.4 million on July 8, 2026. The transaction generated net proceeds of $17.5 million, of which $8.5 million was used to partially repay borrowings, resulting in a $1.1 million loss on debt extinguishment. Pro forma results show the disposition reduces rental revenue and expenses but does not materially change the company's net loss position, with pro forma net loss per share remaining at $(0.09) for Q1 2026 and widening to $(0.51) for FY 2025 (from $(0.43) historical).

• · The sale was completed on July 8, 2026, pursuant to a Purchase and Sale Agreement dated May 26, 2026, as amended on June 30, 2026.
• · No material relationships existed between the Seller and Buyer or their affiliates other than the Agreement.
• · Pro forma total assets decrease from $881.8M to $864.9M, and total liabilities decrease from $285.4M to $277.4M.
• · Pro forma rental revenue for FY 2025 declines by $4.2M to $103.0M, and for Q1 2026 declines by $1.1M to $25.2M.
• · Pro forma net loss for FY 2025 worsens from $(45.0M) historical to $(52.7M) pro forma, primarily due to the nonrecurring loss on sale of $7.9M.
• · The company remains a qualified REIT with no federal income tax provision on real estate operations.

13-07-2026

Tavia Acquisition Corp. (Nasdaq: TAVI) and Vita Inclinata Technologies, Inc. announced a non-binding Letter of Intent for a business combination that would take Vita public via a de-SPAC transaction. The proposed deal values Vita at a pre-money enterprise value of $450 million, contingent on Vita completing a pending strategic acquisition in the defense and industrials market. A definitive agreement is expected within 30 days, with a closing targeted for Q4 2026, though no assurances can be made that the transaction will be consummated.

• · The LOI is non-binding and no definitive agreement has been reached.
• · Tavia and Vita are engaged in initial non-binding investment indications from institutional investors and strategic partners; firm commitments will be announced with a definitive agreement.
• · The transaction is subject to completion of due diligence, negotiation of a definitive agreement, board and equity holder approvals, regulatory approvals, and other customary closing conditions.
• · No financial metrics (revenue, EBITDA, etc.) for Vita were disclosed in the filing.

13-07-2026

Launch One Acquisition Corp. shareholders approved an amendment to extend the company's business combination deadline from 24 months post-IPO to January 15, 2027, at an extraordinary general meeting held on July 10, 2026. The amendment provides additional time to complete an acquisition, reflecting ongoing efforts to identify a target. No financial figures or performance metrics were disclosed in this filing.

• · The extraordinary general meeting was held on July 10, 2026 at 10:00am Eastern Time at Ellenoff Grossman & Schole LLP, New York.
• · The amendment changes the Completion Window definition to end on January 15, 2027, or earlier/later as approved by directors or members.
• · The original deadline was 24 months after the IPO closing date.

13-07-2026

SC II Acquisition Corp. (SCIIU) announced on July 12, 2026, that it has terminated its non-binding letter of intent with an unnamed payments technology company, effective immediately, and will not pursue the proposed business combination. The termination leaves the SPAC without a target and with no further obligations under the LOI except for confidentiality provisions. This development increases uncertainty regarding the company's ability to complete an initial business combination within its available timeframe.

• · The LOI was entered into on March 31, 2026, and terminated on July 12, 2026.
• · The target was a payments technology company (not named).
• · The company retains confidentiality obligations under the LOI.
• · SC II Acquisition Corp. is a blank check company (SPAC) listed on Nasdaq under tickers SCIIU, SCII, and SCIIR.

13-07-2026

Edgewise Therapeutics completed the sale of sevasemten and its muscular dystrophy business to Servier for $1.55 billion in upfront cash and up to $1.1 billion in milestones, for total potential consideration of up to $2.65 billion. The transaction strengthens Edgewise's balance sheet and sharpens its focus on its cardiovascular pipeline, including EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF, and EDG-003. The company expects to initiate a Phase 3 trial for EDG-7500 in Q4 2026 and a Phase 2 trial for EDG-15400 in HFpEF, with upfront proceeds expected to fully fund EDG-7500 through potential approval.

• · The GRAND CANYON pivotal cohort in Becker is fully enrolled with 175 participants and powered at >98% to show a statistically significant difference vs placebo, with top-line data expected in Q4 2026.
• · Sevasemten has FDA Orphan Drug Designation for Becker and Duchenne, Rare Pediatric Disease Designation for Duchenne, Fast Track designations for both, and EMA Orphan Drug Designations for both.
• · In the MESA open-label extension study, participants maintained stable NSAA scores over more than three years, contrasting with expected functional decline from natural history data.
• · Sevasemten has had no discontinuations or dose reductions due to adverse events.
• · Approximately 12,000 individuals are affected by Becker muscular dystrophy in the U.S., EU-5, and Japan.

13-07-2026

Plum Acquisition Corp. III filed an 8-K on July 13, 2026, furnishing unaudited pro forma financial statements of Tactical Resources Corp. in connection with the previously announced business combination among Plum, Tactical, and Plum III Merger Corp. The pro forma balance sheet shows combined total assets of $39.2M as of April 30, 2026, including $30M in inventory from the crushed aggregate acquisition. The filing includes extensive forward-looking statements and risk factors, and the pro forma information is for illustrative purposes only.

• · The pro forma balance sheet includes a $30M inventory adjustment from the crushed aggregate inventory acquisition.
• · Cash held in trust account is reduced to zero after adjustments.
• · Promissory note – related party is eliminated through settlement entries.
• · The filing is dated July 13, 2026, but the earliest event reported is April 7, 2026.

13-07-2026

Calisa Acquisition Corp (ALISR) filed an 8-K on July 13, 2026, disclosing that its merger target, GoodVision AI Inc., has joined the NVIDIA Connect program. This development is a positive milestone for GoodVision ahead of the proposed business combination, but the filing contains no financial figures or performance metrics, and the transaction remains subject to shareholder approval and regulatory conditions.

• · GoodVision AI Inc. joined the NVIDIA Connect program on July 8, 2026.
• · The business combination between Calisa Acquisition Corp and GoodVision is governed by a Business Combination Agreement (BCA).
• · The Company's securities trade on Nasdaq: Units (ALISU), Ordinary Shares (ALIS), Rights (ALISR).
• · The Company is an emerging growth company and has not elected to use the extended transition period for complying with new financial accounting standards.
• · A Registration Statement including a Proxy Statement/Prospectus has been filed with the SEC for the proposed transaction.

13-07-2026

Esperion Therapeutics has entered into a Contingent Value Rights (CVR) Agreement in connection with its acquisition by Essence Parent Inc. (backed by ArchiMed SAS) via merger. Under the agreement, former Esperion shareholders and certain equity award holders may receive milestone payments based on U.S. net sales of NEXLETOL/NEXLIZET (bempedoic acid products) and ENBUMYST (bumetanide nasal spray). The Bempedoic Acid Milestone requires annual net sales above $300 million in 2027, while the Enbumyst Milestone requires annual net sales of at least $160 million in any single calendar year through 2030. The CVRs are nontransferable and carry no voting or dividend rights.

• · The CVR Agreement is dated July 13, 2026, and was entered into pursuant to the Merger Agreement dated May 1, 2026.
• · CVRs are issued to holders of Shares receiving Merger Consideration, certain Company Equity Awards, Company Warrants, and Convertible Notes.
• · The Bempedoic Acid Milestone Period runs from January 1, 2027 to December 31, 2027.
• · The Enbumyst Milestone Period runs from the Effective Time until the earlier of the year the milestone is achieved or December 31, 2030.
• · CVRs are nontransferable, except in limited circumstances such as inheritance or by operation of law.
• · Holders have no voting rights, dividends, or interest on the CVRs.
• · The agreement includes a 'Diligent Efforts' covenant requiring the company to use efforts comparable to a biopharmaceutical company of similar size to commercialize the products, without considering the potential milestone payments.
• · The Rights Agent is Computershare Inc. and Computershare Trust Company, N.A., acting jointly.

13-07-2026

Inception Growth Acquisition Ltd deposited $12,203.33 into its trust account to extend the deadline for completing a business combination by one month, from July 13, 2026 to August 13, 2026. The extension provides additional time to finalize a merger or acquisition, but the company has not yet announced a target or definitive agreement.

• · The extension is from July 13, 2026 to August 13, 2026 (one month).
• · The company's securities trade on OTC Markets Group, Inc. under symbols IGTAU (units), IGTA (common stock), IGTAW (warrants), and IGTAR (rights).
• · The company is a blank check company (SPAC) incorporated in Delaware.